Hydrocortisone/Neomycin/Polymyxin B Ophthalmic Suspension Rx
Generic Name and Formulations:
Hydrocortisone 10mg, Neomycin (as sulfate) 3.5mg, polymyxin B sulfate 10000 Units; per mL; contains thimersol.
Various generic manufacturers
Indications for Hydrocortisone/Neomycin/Polymyxin B Ophthalmic Suspension:
For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
1 or 2 drops in affected eye(s) every 3 or 4 hours, depending on severity. Max initial ℞: 20mL; do not refill without further evaluation.
Ocular fungal, viral or mycobacterial infections.
Do not inject into the eye. Corneal or scleral thinning. Glaucoma. Monitor IOP, and for secondary infections in prolonged use. Discontinue if sensitization reaction occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Antibiotics + steroid.
Local irritation, sensitization (itching, swelling, conjunctival erythema), masks infection, delays healing; in prolonged use: increased IOP, cataracts, corneal perforation, optic nerve damage.
Formerly known under the brand name Cortisporin Ophthalmic.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib